info:eu-repo/semantics/article
COVID-19 convalescent plasma composition and immunological effects in severe patients
Registro en:
Anaya JM, Rojas M, Salinas ML., Rodríguez Y, Roa G, Lozano M, Rodríguez Jiménez M, Montoya N, Zapata E, Monsalve DM, Acosta Ampudia Y, Ramírez Santana C. Post-COVID syndrome. A case series and comprehensive review Autoimmunity Reviews, Volume 20, 2021
0896-8411
10.1016/j.jaut.2021.102598
1095-9157
Autor
Acosta Ampudia, Yeny
Monsalve, Diana M.
Rojas, Manuel
Rodríguez, Yhojan
Gallo, Juan Esteban
Salazar Uribe, Juan Carlos
Santander, María José
Cala, Mónica P.
Zapata Builes, Wildeman
Zapata Cardona, María Isabel
Manrique, Rubén
Pardo Oviedo, Juan Mauricio
Camacho, Bernardo
Ramírez Santana, Carolina
Anaya Cabrera, Juan Manuel
Institución
Resumen
ABSTRACT: Convalescent plasma (CP) has emerged as a treatment for COVID-19. However, the composition and mechanism of action are not fully known. Therefore, we undertook a two-phase controlled study in which, first the immunological and metabolomic status of recovered and severe patients were evaluated. Secondly, the 28-day effect of CP on the immune response in severe patients was assessed. Nineteen recovered COVID-19 patients, 18 hospitalized patients with severe disease, and 16 pre-pandemic controls were included. Patients with severe disease were treated with CP transfusion and standard therapy (i.e., plasma recipients, n = 9) or standard therapy alone (n = 9). Clinical and biological assessments were done on day 0 and during follow-up on days 4, 7, 14, and 28. Clinical parameters, viral load, total immunoglobulin (Ig) G and IgA anti-S1-SARS-CoV-2 antibodies, neutralizing antibodies (NAbs), autoantibodies, cytokines, T and B cells, and metabolomic and lipidomic profiles were examined. Total IgG and IgA anti-S1-SARS-CoV-2 antibodies were key factors for CP selection and correlated with NAbs. In severe COVID-19 patients, mostly interleukin (IL)-6 (P = <0.0001), IL-10 (P = <0.0001), IP-10 (P = <0.0001), fatty acyls and glycerophospholipids were higher than in recovered patients. Latent autoimmunity and anti–IFN–α antibodies were observed in both recovered and severe patients. COVID-19 CP induced an early but transient cytokine profile modification and increases IgG anti-S1-SARS-CoV-2 antibodies. At day 28 post-transfusion, a decrease in activated, effector and effector memory CD4+ (P < 0.05) and activated and effector CD8+ (P < 0.01) T cells and naïve B cells (P = 0.001), and an increase in non-classical memory B cells (P=<0.0001) and central memory CD4+ T cells (P = 0.0252) were observed. Moreover, IL-6/IFN-γ (P = 0.0089) and IL-6/IL-10 (P = 0.0180) ratios decreased in plasma recipients compared to those who received standard therapy alone. These results may have therapeutic implications and justify further post-COVID-19 studies. 0012444